← Back
Data updated: Mar 29, 2026
PARKE DAVIS
NeurologyInfectious DiseaseDermatology
Big Pharma
PARKE DAVIS is a major pharmaceutical company focused on Neurology, Infectious Disease, Dermatology.
1953
Since
74
Drugs
-
Trials
131
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 57%
4 drugs
Infectious Disease 29%
2 drugs
Dermatology 14%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Discontinued (66)
HEPARIN SODIUM MEPERIDINE HYDROCHLORIDE ISOPROTERENOL HYDROCHLORIDE DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE METHYLTESTOSTERONE INDOMETHACIN HYDROCORTISONE THIAMINE HYDROCHLORIDE HEPARIN LOCK FLUSH METHYLDOPA CHLORDIAZEPOXIDE HYDROCHLORIDE ERYTHROMYCIN ETHYLSUCCINATE METHYLDOPA AND HYDROCHLOROTHIAZIDE PENICILLIN G POTASSIUM ERYC NITROSTAT CELONTIN MEPROBAMATE TOLBUTAMIDE CHLOROMYCETIN HUMATIN HYDROCORTISONE ACETATE TRIPELENNAMINE HYDROCHLORIDE FEMPATCH ELASE-CHLOROMYCETIN ISOETHARINE HYDROCHLORIDE PROCAN SR CENTRAX ESTROVIS SODIUM PENTOBARBITAL SECOBARBITAL SODIUM MECLOMEN SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE UTICORT PROMAPAR PARACORT ERYPAR MILONTIN SULFALAR NORLUTATE ERYC 125 AMBODRYL NORLUTIN UTIMOX NORLESTRIN 28 1/50 NORLESTRIN FE 2.5/50 PROCAN BENYLIN PITRESSIN TANNATE PARSIDOL
+16 more
Company Info
- First Approval
- 1953-09-08
- Latest
- 2022-04-28
- Applications
- 105